vs
FIRST FINANCIAL BANCORP（FFBC）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
FIRST FINANCIAL BANCORP的季度营收约是Ultragenyx Pharmaceutical Inc.的1.3倍（$271.5M vs $207.3M），FIRST FINANCIAL BANCORP净利率更高（27.4% vs -62.0%，领先89.4%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 12.4%）
第一金融银行集团是总部位于美国俄亥俄州辛辛那提的区域性银行，运营中心设于辛辛那提北郊斯普林代尔及印第安纳州格林斯堡。该行成立于1863年，拥有美国第六悠久的国家银行牌照，在俄亥俄、印第安纳、肯塔基、伊利诺伊四州共设有131个营业网点，2009年9月曾在政府协助下收购欧文金融公司及其子公司。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
FFBC vs RARE — 直观对比
营收规模更大
FFBC
是对方的1.3倍
$207.3M
净利率更高
FFBC
高出89.4%
-62.0%
两年增速更快
RARE
近两年复合增速
12.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $271.5M | $207.3M |
| 净利润 | $74.4M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | — | -54.7% |
| 净利率 | 27.4% | -62.0% |
| 营收同比 | — | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益（稀释后） | $0.71 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FFBCRARE
| Q1 26 | $271.5M | — | ||
| Q4 25 | $238.8M | $207.3M | ||
| Q3 25 | $234.0M | $159.9M | ||
| Q2 25 | $226.3M | $166.5M | ||
| Q1 25 | $200.4M | $139.3M | ||
| Q4 24 | $224.3M | $164.6M | ||
| Q3 24 | $201.3M | $139.5M | ||
| Q2 24 | $214.8M | $147.0M |
净利润FFBCRARE
| Q1 26 | $74.4M | — | ||
| Q4 25 | — | $-128.6M | ||
| Q3 25 | $71.9M | $-180.4M | ||
| Q2 25 | $70.0M | $-115.0M | ||
| Q1 25 | $51.3M | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | $52.5M | $-133.5M | ||
| Q2 24 | $60.8M | $-131.6M |
营业利润率FFBCRARE
| Q1 26 | — | — | ||
| Q4 25 | — | -54.7% | ||
| Q3 25 | 38.7% | -106.9% | ||
| Q2 25 | 38.8% | -64.8% | ||
| Q1 25 | 31.7% | -102.6% | ||
| Q4 24 | — | -74.3% | ||
| Q3 24 | 32.2% | -94.6% | ||
| Q2 24 | 34.8% | -79.1% |
净利率FFBCRARE
| Q1 26 | 27.4% | — | ||
| Q4 25 | — | -62.0% | ||
| Q3 25 | 30.7% | -112.8% | ||
| Q2 25 | 30.9% | -69.0% | ||
| Q1 25 | 25.6% | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | 26.1% | -95.7% | ||
| Q2 24 | 28.3% | -89.5% |
每股收益（稀释后）FFBCRARE
| Q1 26 | $0.71 | — | ||
| Q4 25 | $0.64 | $-1.28 | ||
| Q3 25 | $0.75 | $-1.81 | ||
| Q2 25 | $0.73 | $-1.17 | ||
| Q1 25 | $0.54 | $-1.57 | ||
| Q4 24 | $0.68 | $-1.34 | ||
| Q3 24 | $0.55 | $-1.40 | ||
| Q2 24 | $0.64 | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $421.0M |
| 总债务越低越好 | $13.1M | — |
| 股东权益账面价值 | $2.9B | $-80.0M |
| 总资产 | $22.5B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资FFBCRARE
| Q1 26 | — | — | ||
| Q4 25 | — | $421.0M | ||
| Q3 25 | — | $202.5M | ||
| Q2 25 | — | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | — | $150.6M | ||
| Q2 24 | — | $480.7M |
总债务FFBCRARE
| Q1 26 | $13.1M | — | ||
| Q4 25 | $514.1M | — | ||
| Q3 25 | $221.8M | — | ||
| Q2 25 | $345.0M | — | ||
| Q1 25 | $345.9M | — | ||
| Q4 24 | $347.5M | — | ||
| Q3 24 | $344.1M | — | ||
| Q2 24 | $338.6M | — |
股东权益FFBCRARE
| Q1 26 | $2.9B | — | ||
| Q4 25 | $2.8B | $-80.0M | ||
| Q3 25 | $2.6B | $9.2M | ||
| Q2 25 | $2.6B | $151.3M | ||
| Q1 25 | $2.5B | $144.2M | ||
| Q4 24 | $2.4B | $255.0M | ||
| Q3 24 | $2.5B | $346.8M | ||
| Q2 24 | $2.3B | $432.4M |
总资产FFBCRARE
| Q1 26 | $22.5B | — | ||
| Q4 25 | $21.1B | $1.5B | ||
| Q3 25 | $18.6B | $1.2B | ||
| Q2 25 | $18.6B | $1.3B | ||
| Q1 25 | $18.5B | $1.3B | ||
| Q4 24 | $18.6B | $1.5B | ||
| Q3 24 | $18.1B | $1.5B | ||
| Q2 24 | $18.2B | $1.6B |
负债/权益比FFBCRARE
| Q1 26 | 0.00× | — | ||
| Q4 25 | 0.19× | — | ||
| Q3 25 | 0.08× | — | ||
| Q2 25 | 0.13× | — | ||
| Q1 25 | 0.14× | — | ||
| Q4 24 | 0.14× | — | ||
| Q3 24 | 0.14× | — | ||
| Q2 24 | 0.15× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
经营现金流FFBCRARE
| Q1 26 | — | — | ||
| Q4 25 | $337.9M | $-99.8M | ||
| Q3 25 | $89.8M | $-91.4M | ||
| Q2 25 | $69.8M | $-108.3M | ||
| Q1 25 | $56.1M | $-166.5M | ||
| Q4 24 | $262.2M | $-79.3M | ||
| Q3 24 | $88.1M | $-67.0M | ||
| Q2 24 | $68.1M | $-77.0M |
自由现金流FFBCRARE
| Q1 26 | — | — | ||
| Q4 25 | $317.1M | $-100.8M | ||
| Q3 25 | $85.8M | $-92.7M | ||
| Q2 25 | $64.8M | $-110.7M | ||
| Q1 25 | $52.4M | $-167.8M | ||
| Q4 24 | $241.1M | $-79.5M | ||
| Q3 24 | $84.4M | $-68.6M | ||
| Q2 24 | $64.8M | $-79.0M |
自由现金流率FFBCRARE
| Q1 26 | — | — | ||
| Q4 25 | 132.8% | -48.6% | ||
| Q3 25 | 36.7% | -58.0% | ||
| Q2 25 | 28.6% | -66.5% | ||
| Q1 25 | 26.1% | -120.5% | ||
| Q4 24 | 107.5% | -48.3% | ||
| Q3 24 | 42.0% | -49.2% | ||
| Q2 24 | 30.2% | -53.7% |
资本支出强度FFBCRARE
| Q1 26 | — | — | ||
| Q4 25 | 8.7% | 0.5% | ||
| Q3 25 | 1.7% | 0.8% | ||
| Q2 25 | 2.2% | 1.5% | ||
| Q1 25 | 1.9% | 1.0% | ||
| Q4 24 | 9.4% | 0.1% | ||
| Q3 24 | 1.8% | 1.2% | ||
| Q2 24 | 1.5% | 1.4% |
现金转化率FFBCRARE
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.25× | — | ||
| Q2 25 | 1.00× | — | ||
| Q1 25 | 1.09× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.68× | — | ||
| Q2 24 | 1.12× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FFBC
| Net Interest Income | $189.6M | 70% |
| Noninterest Income | $81.9M | 30% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
